

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of December 2018**

	31.12.2018	31.12.2017
	BGN'000	BGN'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	25 166	26 803
Intangible assets	2 871	2 998
Investment in minority interest	1	1
Trade receivables	6 853	5 960
<b>Total non-current assets</b>	<b>34 891</b>	<b>35 762</b>
<b>Current assets</b>		
Inventories	5 491	5 190
Trade and other receivables	69 775	55 998
Treasury shares redeemed	92	8
Current corporate income tax	4	
Cash and cash equivalents	250	24
<b>Total current assets</b>	<b>75 612</b>	<b>61 220</b>
<b>Total assets</b>	<b>110 503</b>	<b>96 982</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	72 200	64 300
Reserves	10 084	9 172
Retained earnings	11 352	8 831
<b>Total</b>	<b>93 636</b>	<b>82 303</b>
<b>Non-current liabilities</b>		
Long-term loans	324	590
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	119	83
<b>Total non-current liabilities</b>	<b>1 751</b>	<b>1 981</b>
<b>Current liabilities</b>		
Trade and other liabilities	4 195	2 134
Short-term loans	9 777	9 784
Current portion of long-term loans	265	491
Current corporate income tax		78
Other tax liabilities	879	211
<b>Total current liabilities</b>	<b>15 116</b>	<b>12 698</b>
<b>Total liabilities</b>	<b>16 867</b>	<b>14 679</b>
<b>Total equity and liabilities</b>	<b>110 503</b>	<b>96 982</b>

Date of preparation: 25.01.2019

Sofia

Prepared by:.....

/ P. Moneva /



Executive Director:.....

/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of December 2018**

	<b>31.12.2018</b>	<b>31.12.2017</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	38 464	33 359
Other income	46	76
<b>Total income</b>	<b>38 510</b>	<b>33 435</b>
Carrying amount of goods sold	(2 326)	(1 719)
Changes in inventories of finished products and work in progress	(118)	432
Materials and services	(13 605)	(13 726)
Personnel expenses	(3 890)	(3 544)
Depreciation / amortisation expenses	(3 272)	(3 084)
Other expenses	(2 406)	(1 692)
Finance income	17	88
Finance costs	(438)	(381)
<b>Total expenses</b>	<b>(26 038)</b>	<b>(23 626)</b>
<b>Profit before taxation</b>	<b>12 472</b>	<b>9 809</b>
Corporate income tax expense	(1 120)	(978)
<b>Profit/Loss for the period</b>	<b>11 352</b>	<b>8 831</b>
<b>Total comprehensive income for the period</b>		
Earnings per share / in BGN per 1 share /	0.16	0.14

Date of preparation: 25.01.2019

Sofia

Prepared by: .....  
 / P. Moneva /



Executive Director: .....  
 /B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of December 2018**

	31.12.2018	31.12.2017
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	28 229	30 929
Payments to suppliers of materials, goods and services	(13 818)	(15 539)
Payments to personnel	(3 472)	(3 456)
Payments of interest and dividends	(21)	(16)
Corporate income tax payments	(1 291)	(989)
Other proceeds / payments	(7 285)	(5 534)
<b>Net cash flows</b>	<b>2 342</b>	<b>5 395</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(1 399)	(2 757)
<b>Net cash flows</b>	<b>(1 399)</b>	<b>(2 757)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	188	172
Payments on loans	(188)	(1 738)
Payment of interest, dividends	(196)	(224)
Payments on finance lease	(527)	(866)
Other proceeds/payments	6	(8)
<b>Net cash flows</b>	<b>(717)</b>	<b>(2 664)</b>
<b>Change in cash and cash equivalents</b>		
Cash and cash equivalents at the beginning of the period	24	50
Cash and cash equivalents at the end of the period	250	24

Date of preparation: 25.01.2019

Sofia

Prepared by:.....

/ P. Moneva /



Executive  
Director:.....

/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as 31 of December 2018**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2017</b>	<b>56 600</b>	<b>3 149</b>	<b>4 661</b>	<b>8 585</b>	<b>72 995</b>
Profit/loss for the period				8 831	8 831
Other comprehensive income		477			477
Including from tax effect of the revaluation of property, plant and equipment		(60)			(60)
<b>Total comprehensive income</b>		<b>477</b>		<b>8 831</b>	<b>9 308</b>
Issue of shares by the owners	7 700			(7 700)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			885	(885)	
<b>Total amount of income and expenses recognised during the period</b>	<b>7 700</b>		<b>885</b>	<b>(8 585)</b>	
<b>Balance as of 31.12.2017</b>	<b>64 300</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
<b>Balance as of 01.01.2018</b>	<b>64 300</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
Profit/loss for the period				11 352	11 352
Other comprehensive income		(19)			(19)
<b>Total comprehensive income</b>		<b>3 607</b>		<b>11 352</b>	<b>11 352</b>
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			931	(931)	
<b>Total amount of income and expenses recognised during the period</b>					
<b>Balance as of 31.12.2018</b>	<b>72 200</b>	<b>3 607</b>	<b>6 477</b>	<b>11 352</b>	<b>93 636</b>

Date of preparation: 25.01.2019  
Sofia

Prepared by:.....  
/P. Moneva/



Executive Director:.....  
/B. Georgiev /